Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Oruka Therapeutics, Inc.NASDAQ: ORKA

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow dips below year-ago levels

Q3 FY2026 financing cash flow of $126.77M fell 25.4% year over year, behind the +390.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 80.9% from the prior quarter.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -25.4% toward the trailing-twelve-month pace of +390.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$126.77M-80.9% QoQ
Last fiscal yearDec 2025
$170.32M-62.1% YoY
LTMSep 2026
$830.71M+390.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.4%——
1 year-62.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
170.32M USD
Year-over-year change
-62.1%
5-year CAGR
+28.6%

Financing Cash Flow vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's LTM Sep 2026 financing cash flow of $830.71M is the 2nd largest of the 10 companies compared; the peer median is $103.52M.
  • Its year-over-year change of +390.1% is the 2nd highest of 10, against a peer median of +40.9%.
ORKA Competitors Peer median
Financing Cash Flow for ORKA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$1.03B +2428.7%+42.6%54053.9%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$830.71M +390.1%——
ALMSAlumis Inc. Common StockLTM Jun 2026$360.93M +53.0%-72.7%4878.8%
ATTOAttovia Therapeutics, Inc.FY2025$142.01M +71.6%—10519.4%
ZURAZura Bio LimitedLTM Mar 2026$127.78M +11.1%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$103.52M +40.9%+6.8%—
ANABAnaptysBio, Inc.LTM Mar 2026$102.81M -191.7%—44.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.19M -29.8%—623.8%
XNCRXencor, Inc.LTM Jun 2026$8.3M -95.9%+13.0%7.9%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M +381.5%—1707.8%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ORKA) $103.52M+40.9%+9.9%1707.8%

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2020
Dec 2020
FY2021
Dec 2021
FY2022
Dec 2022
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.74M)(19.32M)(9.93M)(83.72M)(105.43M)
Depreciation & Amortization93K91K114K27K83K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.88M(28K)(1.66M)11.59M(2.56M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.1M(411K)(783K)3.46M693K
Other Working Capital776K383K(878K)8.13M(3.25M)
Other Non-Cash Items43K497K561K14.27M19.7M
Operating Cash Flow(7.73M)(18.76M)(10.91M)(57.84M)(88.21M)
Capital Expenditures(19K)(43K)(2K)(189K)(209K)
Acquisitions (Net)00000
Purchases of Investments000(329.94M)(520.96M)
Sales of Investments0000424.42M
Other Investing Activities00000
Investing Cash Flow(19K)(43K)(2K)(330.13M)(96.75M)
Debt Repayment(408K)0000
Common Stock Issued48.86M23.09M0449.54M170.32M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow48.45M23.09M0449.54M170.32M
Effect of Forex Changes000(37.43M)0
Net Change in Cash40.71M4.29M(10.91M)24.14M(14.64M)
Free Cash Flow(7.74M)(18.81M)(10.91M)(58.03M)(88.42M)

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.